Last updated: 5 May 2022 at 6:58pm EST

Capital Ix, Llc Vivo Capita... Net Worth




The estimated Net Worth of Capital Ix, Llc Vivo Capita... is at least $93 Million dollars as of 5 May 2022. Capital Capita owns over 5,374 units of Tarsus Pharmaceuticals stock worth over $78,514,232 and over the last 4 years Capital sold TARS stock worth over $14,462,348.

Capital Capita TARS stock SEC Form 4 insiders trading

Capital has made over 6 trades of the Tarsus Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently Capital sold 5,374 units of TARS stock worth $65,832 on 5 May 2022.

The largest trade Capital's ever made was selling 512,956 units of Tarsus Pharmaceuticals stock on 2 May 2022 worth over $6,868,481. On average, Capital trades about 171,006 units every 94 days since 2020. As of 5 May 2022 Capital still owns at least 2,469,001 units of Tarsus Pharmaceuticals stock.

You can see the complete history of Capital Capita stock trades at the bottom of the page.



Insiders trading at Tarsus Pharmaceuticals

Over the last 4 years, insiders at Tarsus Pharmaceuticals have traded over $38,362,333 worth of Tarsus Pharmaceuticals stock and bought 1,047,656 units worth $16,525,269 . The most active insiders traders include Investments, Lpwong Roderic..., Capital Ix, Llc Vivo Capita..., and William J Phd Link. On average, Tarsus Pharmaceuticals executives and independent directors trade stock every 10 days with the average trade being worth of $729,047. The most recent stock trade was executed by William J Phd Link on 12 August 2024, trading 35,000 units of TARS stock currently worth $912,800.



What does Tarsus Pharmaceuticals do?

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.



What does Tarsus Pharmaceuticals's logo look like?

Tarsus Pharmaceuticals, Inc. logo

Complete history of Capital Capita stock trades at Tarsus Pharmaceuticals

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
5 May 2022 Capital Ix, Llc Vivo Capita...
Sale 5,374 $12.25 $65,832
5 May 2022
2,469,001
2 May 2022 Capital Ix, Llc Vivo Capita...
Sale 512,956 $13.39 $6,868,481
2 May 2022
2,474,375
23 Jun 2021 Capital Ix, Llc Vivo Capita...
Sale 55,684 $29.79 $1,658,826
23 Jun 2021
2,987,331
21 Jun 2021 Capital Ix, Llc Vivo Capita...
Sale 201,620 $29.05 $5,857,061
21 Jun 2021
3,043,015
14 Apr 2021 Capital Ix, Llc Vivo Capita...
Sale 400 $30.37 $12,148
14 Apr 2021
3,244,635
20 Oct 2020 Capital Ix, Llc Vivo Capita...
Buy 250,000 $16.00 $4,000,000
20 Oct 2020
3,245,035


Tarsus Pharmaceuticals executives and stock owners

Tarsus Pharmaceuticals executives and other stock owners filed with the SEC include: